Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
07/2005
07/26/2005CA2145647C Base polymer for transdermal absorption preparation
07/26/2005CA2145072C Transfer process for making transdermal therapeutic systems
07/26/2005CA2096430C Use of an organopolysiloxane and an acrylamide/neutralized 2-acrylamido-2-methylpropanesulfonic acid cured copolymer in cosmetics or topical applications
07/21/2005WO2005066410A1 Allergen suppressor, allergen-suppression processed fiber and method of producing the same
07/21/2005WO2005066238A1 Medicinal compositions and method for the preparation thereof
07/21/2005WO2005066215A1 Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
07/21/2005WO2005066214A1 Hyaluronic acid derivative and drug containing the same
07/21/2005WO2005065726A1 Pharmaceutical composition
07/21/2005WO2005065721A2 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
07/21/2005WO2005065717A2 Liquid formulations of antibody conjugates
07/21/2005WO2005065716A1 Hard capsule and method for producing same
07/21/2005WO2005065715A1 Method of improving suitability for granulation
07/21/2005WO2005065714A1 Intranasal administration of glucose-regulating peptides
07/21/2005WO2005065713A2 Topically applied medicament for animals
07/21/2005WO2005065709A2 Lyophilized antibody conjugate formulation
07/21/2005WO2005065706A1 Pharmaceutical composition for thrombin peptide derivatives
07/21/2005WO2005065697A1 Method for the photostabilisation of phycobiliproteins in an aqueous extract, compositions containing stabilised phycobiliproteins and use of stabilised phycobiliproteins
07/21/2005WO2005065687A1 Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
07/21/2005WO2005065685A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
07/21/2005WO2005065682A2 Rabeprazole containing formulation
07/21/2005WO2005065674A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
07/21/2005WO2005065673A1 Atomoxetine formulations
07/21/2005WO2005065665A2 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
07/21/2005WO2005065664A1 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
07/21/2005WO2005065663A1 Rosiglitazone and metformin formulations
07/21/2005WO2005065662A1 Solid dosage formulations of galantamine
07/21/2005WO2005065661A2 Immediate, controlled and sustained release formulations of galanthamine
07/21/2005WO2005065660A2 Ziprasidone formulations
07/21/2005WO2005065659A1 Consumer customized dosage forms
07/21/2005WO2005065658A1 Cefuroxime axetil granule and process for the preparation thereof
07/21/2005WO2005065657A2 Solid compositions of low-solubility drugs and poloxamers
07/21/2005WO2005065656A2 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
07/21/2005WO2005065655A2 Method for producing keto-l-gulonic acid spray granules
07/21/2005WO2005065654A2 Rosiglitazone formulations
07/21/2005WO2005065653A1 Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
07/21/2005WO2005065652A1 Non-aqueous composition for oral delivery of insoluble bioactive agents
07/21/2005WO2005065651A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
07/21/2005WO2005065650A2 Aerosol formulations comprising a carboxylic acid surfactant
07/21/2005WO2005065649A1 Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid
07/21/2005WO2005065648A2 Novel drug compositions and dosage forms of topiramate
07/21/2005WO2005065647A2 Drug granule coatings that impart smear resistance during mechanical compression
07/21/2005WO2005065646A2 Novel drug compositions and dosage forms
07/21/2005WO2005065645A2 Donepezil formulations
07/21/2005WO2005065644A2 Drug delivery device with mesh based suture tab
07/21/2005WO2005065642A2 Drug delivery device
07/21/2005WO2005065641A2 Non-disintegrating oral solid composition of high dose of water soluble drugs
07/21/2005WO2005065640A1 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
07/21/2005WO2005065639A2 Novel pharmaceutical compositions
07/21/2005WO2005065602A2 Drug delivery device with mechanical locking mechanism
07/21/2005WO2005065435A2 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
07/21/2005WO2005065383A2 Oxidative reductive potential water solution, processes for producing same and methods of using the same
07/21/2005WO2005065319A2 Generally linear effervescent oral fentanyl dosage form and methods of administering
07/21/2005WO2005065318A2 Effervescent oral opiate dosage form
07/21/2005WO2005065317A2 Effervescent oral fentanyl dosage form
07/21/2005WO2005065291A2 Enteric coated aliphatic amine polymer bile acid sequestrants
07/21/2005WO2005065185A2 Temperature-stable formulations, and methods of development thereof
07/21/2005WO2005065121A2 Methods and compositions for the production of monoclonal antibodies
07/21/2005WO2005065069A2 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
07/21/2005WO2005051487A3 A ruminant zinc containing bolus
07/21/2005WO2005051358A8 Composition and method for enhancing bioavailability
07/21/2005WO2005042510A8 Tocopheryl polyethylene glycol succinate articles and process for preparing tpgs articles
07/21/2005WO2005036109A3 Integrating ultraviolet exposure detection devices
07/21/2005WO2005030170A3 Controlled rupture of furtive liposomes
07/21/2005WO2005027879A8 Coated tablets
07/21/2005WO2005020935A3 Method and composition of administering radioprotectants
07/21/2005WO2005018604A3 Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
07/21/2005WO2005018603A3 Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant
07/21/2005WO2005007819A3 Charge-dynamic polymers and delivery of anionic compounds
07/21/2005WO2004100927A3 Injectable depots consisting of liposomal aggregates for the delivery of active substances
07/21/2005WO2004087095A3 Osmotic controlled release device containing zafirlukast and an h1-antagonist
07/21/2005WO2004087045A3 Devices, methods, and compositions to prevent restenosis
07/21/2005WO2004076481A3 Hypoallergenic der p 1 and der p 3 proteins from dermatographoides pteronyssinus
07/21/2005WO2004066903B1 Active drug delivery in the gastrointestinal tract
07/21/2005WO2004060358A3 Method of encapsulating an active lipid-soluble substance by preparing a pit emulsion and emulsion obtained
07/21/2005WO2004024134A8 Pharmaceutical formulations of modafinil
07/21/2005WO2003105811A8 Controlled release compositions and methods for using same
07/21/2005WO2002000207A9 The controlled release preparation of insulin and its method
07/21/2005US20050159822 Particulate acellular tissue matrix
07/21/2005US20050159714 Infusion device and inlet structure for same
07/21/2005US20050159695 Comprises antimicrobial substances, pain relievers, protease inhibitors, kallikrein, and tissue-plasminogen activator
07/21/2005US20050159556 Zwitterionic polymers
07/21/2005US20050159492 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders
07/21/2005US20050159490 Increasing mean cardiac output without materially increasing heart rate utilizing thyroid hormone analog
07/21/2005US20050159441 Active ingredient and solvent can be stored separately until apparatus is used in a nebuliser; propellant-free; active ingredient is present in highly-concentrated form for storage purposes; inhalers
07/21/2005US20050159439 Management of postoperative pain
07/21/2005US20050159410 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
07/21/2005US20050159395 Topical applying to skins; skin disorders; anticarcinogenic agents
07/21/2005US20050159364 Such as trientine; for treatment of neurodegenerative disorders
07/21/2005US20050159360 Improved bioavailability
07/21/2005US20050159344 Forming a carboxy-saccharide derivative of the glycopeptide antibiotic that has a substituent containing a dicarboxylic acid in which one of the carboxylic acid groups is coupled with a saccharide
07/21/2005US20050159337 Use of botulinum toxin therapy for treatment of overactive bladder
07/21/2005US20050159335 Pharmaceutical administration form for peptides, process for its preparation, and use
07/21/2005US20050158856 Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
07/21/2005US20050158410 Method and composition for relieving symptoms of arthritis and gout using fruit of miracles
07/21/2005US20050158408 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
07/21/2005US20050158407 Antipyrotic and method of manufacturing the same
07/21/2005US20050158406 Methods for treating joint inflammation
07/21/2005US20050158396 Comprises extracts selected from of Vaccinium myrtillus, Trifolium pratense, Vitis vinifera and Thea vinensis; group consisting of anthocyanosides, isoflavone glucosides and polyphenols; and a co-active component selected from the group consisting tocopherol, ascorbic acid
07/21/2005US20050158395 Has a first dispensing device for dispensing a jet of the crosslinkable capsule substance, and a device for applying a crosslinking agent to the capsule substance, wherein the crosslinking device has a second dispensing device which directs a jet of the crosslinking agent into the jet; homogeneity
07/21/2005US20050158394 Oral administration of solid dosage forms; multiple unit dosing device comprising a housing and an actuator
1 ... 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 ... 2991